1	Induction of an early IFN- γ cellular response and high plasma levels of SDF-1 α are
2	inversely associated with COVID-19 severity and residence in rural areas in Kenyan
3	patients
4	Short Title : Early IFN- γ response and high SDF-1 α levels linked to Lower COVID-19
5	Severity in rural Kenyan patients
6	Authors
7	Perpetual Wanjiku ^{1*} , Benedict Orindi ¹ , John Kimotho ¹ , Shahin Sayed ² , Reena Shah ² ,
8	Mansoor Saleh ² , Jedidah Mwacharo ¹ , Christopher Maronga ³ , Vivianne Olouch ² , Ann
9	Karanu ² , Jasmit Shah ⁴ , Zaitun Nneka ² , Lynette Isabella Ochola-Oyier ¹⁵ , Abdirahman I.
10	Abdi ¹⁵ , Susanna Dunachie ⁶ , Philip Bejon ¹⁵ , Eunice Nduati ¹⁵ , Francis M. Ndungu ^{15*} .
11	Affiliations
12	¹ Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute
13	(KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
14	² Aga Khan University Hospital, 3rd Parklands Avenue, Nairobi, Kenya.
15	³ Nuffield Department of Population Health, Cancer Epidemiology Unit, University of
16	Oxford, Oxford, United Kingdom.
17	⁴ Brain and Mind Institute and Department of Medicine, Aga Khan University, Nairobi,
18	Kenya.
19	⁵ Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
20	⁶ Nuffield Department of Medicine, Centre for Global Health Research, University of
21	Oxford, Oxford, United Kingdom.
22	
23	* Corresponding authors
24	pwanjiku@kemri-wellcome.org (PW)

25 <u>fndungu@kemri-wellcome.org</u> (FMN) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

27 Introduction

28 COVID-19 was less severe in Sub-Saharan Africa (SSA) compared with Europe and North

- 29 America. It is unclear whether these differences could be explained immunologically. Here
- 30 we determined the levels of *ex vivo* SARS-CoV-2 peptide-specific IFN-γ producing cells, and
- 31 levels of plasma cytokines and chemokines over the first month of COVID-19 diagnosis
- 32 among Kenyan COVID-19 patients from urban and rural areas.

33 Methods

Between June 2020 and August 2022, we recruited and longitudinally monitored 188 34 35 COVID-19 patients from two regions in Kenya, Nairobi (urban, n = 152) and Kilifi (rural, n =36), with varying levels of disease severity - severe, mild/moderate, and asymptomatic. IFN-36 γ secreting cells were enumerated at 0-, 7-, 14- and 28-days post diagnosis by an *ex vivo* 37 38 enzyme-linked immunospot (ELISpot) assay following in vitro stimulation of peripheral blood mononuclear cells (PBMCs) with overlapping peptides from several SARS-CoV-2 39 proteins. A multiplexed binding assay was used to measure the levels of 22 plasma cytokines 40 and chemokines. 41

42 **Results**

Higher frequencies of IFN-γ-secreting cells against the SARS-CoV-2 spike peptides were
observed on the day of diagnosis among the asymptomatic compared to the patients with
severe COVID-19. Higher concentrations of 17 of the 22 cytokines and chemokines
measured were positively associated with severe disease, and in particular interleukin (IL)-8,
IL-18 and IL-1ra (p<0.0001), while a lower concentration of SDF-1α was associated with
severe disease (p<0.0001). Concentrations of 8 and 16 cytokines and chemokines including
IL-18 were higher among Nairobi asymptomatic and mild patients compared to their

respective Kilifi counterparts. Conversely, the concentrations for SDF-1α were higher in rural
Kilifi compared to Nairobi (p=0.012).

52 **Conclusion**

- 53 In Kenya, as seen elsewhere, pro-inflammatory cytokines and chemokines were associated
- 54 with severe COVID-19, while an early IFN-γ cellular response to overlapping SARS-CoV-2
- spike peptides was associated with reduced risk of disease. Living in urban Nairobi
- 56 (compared with rural Kilifi) was associated with increased levels of pro-inflammatory
- 57 cytokines/chemokines.
- 58 Keywords: COVID-19, SARS-CoV-2, IFN-γ-secreting cells, cytokines, chemokines,
- 59 kinetics, Sub-Saharan Africa.

61 Introduction

Despite widespread transmission of SARS-CoV 2, SSA experienced a reduced burden of 62 severe coronavirus disease 2019 (COVID-19) and associated mortality than North America 63 and Europe (1). This observation is both puzzling (2) and paradoxical (3), because of the 64 relatively weaker and underfunded health systems in SSA. Some of the proposed, but still 65 unproven, explanations for the reduced burden of severe COVID-19 in SSA include under-66 diagnosis of cases and mortality, a younger population (7), warmer climatic conditions with 67 outdoor living, high levels of pre-existing cross-protective antibodies and T-cells induced 68 from a high prevalence of infectious agents with SARS-CoV-2 like immune determinants, 69 70 and immune regulation associated with either prior BCG vaccination (5–11) or chronic/repeated infections including helminths (12) and malaria (13). Like other viruses, 71 SARS-CoV-2 induces a plethora of inflammatory host responses, including cytokines and 72 73 chemokines (14), that play key roles in either protective immunity or immunopathology (15). Notably, the pathogenesis of COVID-19 has been linked to dysregulated and excessive 74 cytokine and chemokine responses, upon SARS-CoV-2 infection (16). Numerous studies 75 have linked increased levels of cytokines and chemokines to severe COVID-19 and 76 associated mortality, including IL-1β, IL-1ra, IL-2, IL-6, IL7, IL-8, IL-18, IFN-γ, TNF-α, 77 78 IFN-γ-inducible protein 10 (IP-10), granulocyte macrophage-colony stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), and Macrophage inflammatory protein-79 1 alpha (MIP-1-α) (17–24). Collectively called a "cytokine storm", a dysregulated cytokine 80 81 response is implicated as the cause of the multiple organ failures and the acute respiratory distress syndrome (ARDS), which characterise severed COVID-19 and associated fatalities 82 (25). 83

84 Published data show that the characteristic antibody response to SARS-CoV-2 infection, where levels increase with time, viral loads and COVID-19 severity, were experienced in 85 Kenyan patients (26). Thus, there is no evidence of the primary acute antibody response 86 87 controlling the infection outcome. Aside from antibodies, T-cell responses can control viremia, either directly by killing virus infected cells or indirectly by providing the relevant 88 co-stimulatory molecules for supporting antibody production by B cells (27). However, there 89 is a paucity of data on the cellular response to SARS-CoV-2 in Kenyan patients, and its 90 possible role in modulating disease severity. Furthermore, it is unclear whether the 91 92 differences in the rates of severe disease between urban and rural dwellers within SSA, as well as between developed countries and SSA, could be explained immunologically. In this 93 study, we collected longitudinal blood samples from individuals from Nairobi (urban) and 94 95 Kilifi (rural) with varying degrees of COVID-19 severity (asymptomatic, mild/moderate and severe) and compared levels of their ex vivo SARS-CoV-2 Spike peptide-specific IFN-y 96 producing cells, and levels of plasma cytokines and chemokines over their first month of 97 98 COVID-19 diagnosis.

100 Methods

101 Study design, setting and participants

Participant sampling has been described previously (26). Briefly, we included 400 blood 102 samples from a longitudinal cohort study of 188 patients that aimed at understanding the 103 104 kinetics of naturally acquired immune responses to SARS-CoV-2 among COVID-19 patients from two sites in Kenya: 1) The Aga Khan University Hospital (AKUH) in Nairobi, an urban 105 metropolitan academic medical Centre; and 2) Kilifi County Hospital, a community-based 106 government hospital serving a rural coastal region. The samples were collected during the 107 COVID-19 pandemic between June 2020 and August 2022. At the time of the study, SARS-108 109 CoV-2 transmission in Nairobi was higher than in Kilifi (28). Participants were adults, aged \geq 18 years old, recruited within seven days of positive diagnosis of COVID-19 by RT-PCR 110 testing. Initial sampling was at day 0 (i.e., day of diagnosis). Follow-up and subsequent 111 112 samplings were done on days 7, 14 and 28 from a positive SARS-CoV-2 infection diagnosis. We collected 20 mL of venous blood in sodium heparin vacutainer. Additionally, we 113 included residual longitudinal plasma samples from the AKUH biobank for cytokine and 114 chemokine measurements. These samples were collected from COVID-19 patients who 115 consented to this follow-up study on the day of diagnosis (i.e., day 0) and on day 28. 116

117 COVID-19 severity classification

We included patients from five COVID-19 severity groups of asymptomatic, mild, moderate,
severe, and critical as determined by clinicians at the time of diagnosis following the
National Institutes of Health (NIH, USA) guidelines(29). Asymptomatic patients were those
who tested positive for SARS-CoV-2 via RT-PCR but did not display any COVID-19
symptoms. Mild cases were SARS-CoV-2 positive and exhibited symptoms such as fever,
sore throat, cough, malaise, headache, muscle pain, vomiting, nausea, diarrhoea, anosmia, or

124	ageusia, without any signs of shortness of breath, dyspnea, or abnormal chest imaging.
125	Moderate cases tested positive for SARS-CoV-2 and showed evidence of lower respiratory
126	tract infection based on clinical examination or imaging, with an oxygen saturation (SpO2) of
127	\geq 94% on room air. Severe cases were positive for SARS-CoV-2 with an SpO2 of <94% on
128	room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
129	(PaO2/FiO2) <300 mm Hg, a respiratory rate >30 breaths/minute, and/or lung infiltrates
130	>50%. Critically ill patients were positive for SARS-CoV-2 and experienced respiratory
131	failure, septic shock, and/or multiple organ dysfunction syndrome. Due to the small numbers
132	in the moderate and critical groups, mild cases were lumped together with moderate
133	(mild/moderate), whilst critical were grouped with severe ones (severe). Thus, we studied
134	immune responses among three COVID-19 patient groups: asymptomatic, mild/moderate and
135	severe.

136 **Procedures**

137 Plasma separation and PBMC isolation

Plasma was separated by centrifuging the tubes at 440 g for 10 minutes using an Eppendorf 138 5810R centrifuge, aliquoted in 2 mL microcentrifuge tubes, and immediately stored in -80°C 139 freezers until the time for laboratory analysis. PBMCs were isolated from the remaining 140 blood component using density gradient centrifugation media (LymphoprepTM (1.077 g/ml, 141 Stem Cell Technologies), aliquoted to 1.8 mL cryovials, and stored in -196°C liquid nitrogen 142 tanks until usage. Plasma and PBMC samples from AKUH were transported in dry ice and 143 liquid nitrogen respectively, to the KEMRI-Wellcome Trust Research Programme 144 laboratories in Kilifi and stored appropriately for laboratory analyses. Prior to use, PBMCs 145 were thawed and rested at 37°C, 5% CO₂ for 15–16 hours. PBMC counting was done using 146 Vi-CELL XR Cell Viability Analyser or Countess™ Cell Counting Chamber Slides (Thermo 147 148 Scientific) before assay setup.

149 SARS-CoV-2 synthetic peptides pools for ELISpot measurements

A total of 641 peptides (15–18-mers with a ten amino acid overlap) were pooled into ten 150 peptide pools, spanning different regions of the virus. The pools covered: the spike protein 151 region (S1: positions 1–93 and S2: positions 94–178), membrane protein (M: positions 1–31), 152 nucleocapsid protein (NP: positions 1-55), non-structural proteins (NSP 3B: positions 207-153 306, NSP 3C: position307–379, NSP 12B: positions 665–729 and NSP 15–16: positions 886– 154 972) and Open Reading Frame (ORF3: positions 1–37 and ORF8: positions 1–15). These 155 peptides (which were synthesised by Mimotopes Pty Ltd and a kind donation from Professor 156 Susanna Dunachie's laboratory, Oxford University) were used to stimulate PBMCs for ex 157 vivo IFN-y ELISpot assay. The peptide sequences and pooling details are provided in Table 158 S1. 159

160 Interferon gamma ELISpot assay

To quantify the ex vivo interferon gamma (IFN- γ) cellular response to overlapping SARS-161 CoV-2 peptides from different proteins, we stimulated PBMC with synthetic peptides pools 162 through an *in vitro* IFN- γ ELISpot assay, as previously described (30). Briefly, 5 µg/ml of 163 anti- human IFN-y antibody clone 1-D1K (Mabtech, AB, Sweden) was used to coat 164 Multiscreen-I 96 ELISpot plates overnight. Individual's PBMC were plated in duplicates at 165 200,000 cells per well for each specific protein, based on pre-prepared plate templates. 166 Peptide pools were then added at a final concentration of 2 µg/mL per wells and incubated 167 for 16-18 hours at 37°C, 5% CO₂, 95% humidity. Concanavalin A (ConA; Sigma) was used 168 as the positive control at a final concentration of 5 µg/mL per well, while dimethyl sulfoxide 169 (DMSO; Sigma), which was a constituent of the diluent for the peptides and Con A was used 170 171 at a similar concentration to peptides to serve as the negative control. IFN- γ secreting cells were then detected using an anti-human IFN- γ biotinylated antibody clone 7-B6-1 (Mabtech) 172 at 1 µg/mL and an incubation for 2–4 hours. Thereafter, streptavidin alkaline phosphatase 173

antibody (Mabtech) was added at 1 μ g/mL and incubated for 1–2 hours, and the IFN- γ spots 174 then developed using 1-StepTM NBT/BCI (nitro blue tetrazolium/5-bromo-4-chloro-3-175 phosphatase) substrate (Thermo Scientific) during a 7-minute incubation in the dark. The 176 enzyme-substrate reaction was stopped by rinsing the plate 3 times under running tap water. 177 Plates were then airdried for at least 2 days on an open lab bench, and spots enumerated on an 178 AID ELISpot Reader version 4.0. Results are hereby reported as spot-forming units 179 180 (SFU)/10⁶ PBMC after subtracting the background (mean SFU from negative control wells). Data from failed individual PBMC tests, defined here as either, an excessive 181 182 background where the negative control wells had >80 SFU/10^6 PBMCs, or a positive control well with an average of <100 SFU/10⁶ PBMCs (too few), were excluded. We also 183 applied the ELISpot assay limit of detection of 10 SFU/10⁶ PBMCs, with all wells having 184 values <10 SFU/10⁶ PBMCs replaced with 5 SFU/10⁶ PBMCs. For the participants who 185 186 did not have enough PBMC to be tested against all the peptide pools, we prioritised measurements against pools from S1, S2, NP and M proteins. Data are reported only for the 187 individuals whose PBMC were tested against all the available peptide pools for each specific 188 protein segment. We summed the responses from the different pools of the same protein 189 segment, which resulted in different sample sizes for different proteins as follows: spike (171 190 samples for S1, S2), NP (162 samples), M (136 samples), NSPs (100 samples for NSP 3B, 191 NSP 3C, NSP 12B and NSP 15 -16) and ORF (90 samples for ORF 3 and ORF 8) Table S2. 192

193 Luminex assay

194 Plasma concentrations of 22 cytokines and chemokines were measured using a Human

- 195 ProcartaPlex[™] Human Panel 1A (Thermo Fisher Scientific, Cat. No. EPX010-12010-901,
- 196 Lot number 316776-000), which consisted of: a) Th1/Th2 specific cytokines: GM-CSF, IFN-
- 197 γ , IL-1 β , IL-2, IL-6, IL-8, IL-18, TNF- α , IL-9, IL-21; b) Pro-Inflammatory cytokines: IFN- α ,
- 198 IL-1α, IL-1ra, IL-7, TNF-β; and c) Chemokines: Eotaxin, GRO-α, IP-10, MCP-1, MIP-1α,

MIP-1 β , SDF-1 α , according to the manufacturer's instructions. Briefly, 1x capture magnetic 199 beads were added to the plates, and unbound beads were then washed away with 1X wash 200 buffer. Plasma samples were thawed and diluted at 1:2 with 1X universal assay buffer (UAB) 201 before addition to the plates. Standards from the kit at 4-fold serial dilutions of 1:5, 1:20, 202 1:80, 1:320, 1:1280, 1:5120, 1:20480 as well as a blank (UAB), were also added. The plates 203 were then incubated on a shaker at 600 rpm for 2 hours at room temperature. After 204 205 incubation, contents were discarded, plates washed, and 1X biotinylated detection antibody added. The plates were then incubated for 30 minutes on an Eppendorf Thermomixer 206 207 Comfort shaker at room temperature. The plates were then washed, and 1X Streptavidin-PE added and incubated for 30 minutes on an Eppendorf Thermomixer Comfort shaker at room 208 temperature, the plates were then washed before adding 1X reading buffer for 5 minutes on 209 210 an Eppendorf Thermomixer Comfort shaker at room temperature. All wash steps were performed on an Invitrogen hand-held magnetic plate washer. Data were acquired on the 211 Magpix systems multiplex Luminex machine and concentrations (pg/mL) of the samples 212 calculated in Belysa® Immunoassay Curve Fitting software version 1.1.0 (31) using a 5- or 213 4-parameter logistic standard curve generated from standards of known concentration. 214

215 Statistical analysis

For the ELISpot data, time point specific geometric means (GMs) of IFN-γ secreting cells for
each of the different SARS-COV-2 peptides pools were calculated for each severity group
and geographical location. For each peptide, variations in ELISpot responses were compared
using a linear mixed effects model on log-transformed PBMCs values with patient as a
random effect, and time (i.e., day of sampling), severity group and time-by-severity group
interaction term as fixed effects (32), followed by Tukey's multiple comparisons. Within
each severity group, differences between geographic locations were compared using Kruskal

Wallis paired with a Dunn's multiple comparisons. This analysis set was restricted to 59patients who had PBMC samples.

Cytokine and chemokine data were first normalised to have a zero mean and a standard 225 deviation of one, and cross-correlations among the cytokines determined using Pearson 226 correlations and principal component analysis (PCA). Principal components (PCs) were 227 extracted based on scree-plot, variance explained and the interpretability of the components. 228 Next, the non-normalised cytokine and chemokine data were log-transformed and fitted into 229 linear mixed effects regression models with age, sex, day of sampling, location or disease 230 231 severity as fixed effects and patient as a random effect. Interactions were explored and separate models fitted where necessary. For location comparisons, severe and moderate 232 COVID-19 cases were excluded as these categories were only present in the Nairobi data. 233 Results from the regression models were presented using heat maps, in which the effect size 234 (i.e., coefficient) determined the density of colour-shading for each square. TNF-β data were 235 excluded from the analyses as only one patient had a measurable concentration. Thus, we 236 analysed 21 cytokines from all 188 patients. Analyses were performed using R version 4.3.0 237 (33). The factoextra package (34) was used for PCA. For visualisations, the pheatmap (35) 238 and ggplot2 (36) packages and GraphPad Prism Software version 10.1.2 (37) were used. 239

240 Ethical approval

The study obtained ethical approval from the Kenya Medical Research Institute's Scientific
and Ethics Review Unit (KEMRI SERU; protocol no. 4081) and the Aga Khan University,
Nairobi, Institutional Ethics Review Committee (protocol no. 2020 IERC-135 V2). Written
informed consent was obtained from all willing patients before their enrolment into the study.

246 **Results**

247 Participant baseline characteristics

- Using the NIH clinical guidelines for grading COVID-19 severity of 188 patients, 27 (14%)
- 249 were asymptomatic, 75 (40%) were mild/moderate and 86 (46%) were severe cases.
- 250 Collectively, the 188 patients contributed 400 blood samples collected over the first month of
- diagnosis: day 0 (187 samples), day 7 (50 samples), day 14 (53 samples), and day 28 (110
- samples). Fewer samples were collected on days 7 and 14 mainly due to design; that is,
- residual longitudinal plasma samples from AKUH biobank were only collected in day 0 and
- day 28. Of the 188 patients, 129 (69%) were male, 36 (19%) were from rural Kilifi and 152
- 255 (81%) from urban Nairobi (Table 1). Their median age at recruitment was 48 years (IQR 37–
- 58), with disease severity increasing with age. All 86 patients with severe COVID-19 were
- 257 from Nairobi as we were unable to recruit severe patients in Kilifi. Underlying comorbidities
- such as diabetes, HIV/AIDS, and hypertension were prevalent among the mild/moderate and
- severe COVID-19 groups. Two participants with severe disease died on day 7 and 28
- respectively (Table 1).
- 261 **Table 1.** Participant demographic and clinical characteristics[†]

Characteristic	Asymptomatic	Mild/Moderate	Severe
	(n = 27)	(n = 75)	(n = 86)
Median age at recruitment	40 (33, 55)	46 (35, 54)	53 (43, 60)
(IQR), years			
Male sex	15 (56%)	46 (61%)	68 (79%)
Location			
Kilifi	21 (78%)	15 (20%)	0

Characteristic	Asymptomatic	Mild/Moderate	Severe
	(n = 27)	(n = 75)	(n = 86)
Nairobi	6 (22%)	60 (80%)	86 (100%)
Comorbidities			
Diabetic	1 (7%)	28 (42%)	47 (63%)
Hypertensive	0	15 (22%)	33 (44%)
HIV positive	0	5 (8%)	4 (5%)
Had COPD	0	0	1 (1%)
Had Renal disease	0	0	2 (3%)
Had heart disease	0	0	6 (8%)
Patient management			
Were hospital admissions	0	56 (84%)	75 (100%)
In intensive care unit	0	4 (6.0%)	15 (20%)
Clinical Outcome, died	0	0	2 (3%)

262

[†] Data are median (IQR) or number (%); COPD if Chronic obstructive pulmonary disease.

Kinetics and frequencies of *ex vivo* IFN-y secreting cells by 263

COVID-19 severity and geographical location 264

Kinetics and levels of IFN- γ secreting cell responses were assessed in a subset of 59 265

participants with PBMC samples, contributing 172 samples. At day 0, the frequency of IFN-y 266

secreting cells to overlapping SARS-CoV-2 spike peptide was significantly higher in 267

asymptomatic patients compared to severe patients (GMs: 117 [95% CI 71-194] vs 32 [95% 268

CI 8–76]; p=0.0366) (Figure 1a, Table S3). For the IFN-γ secreting cells specific to 269

270 overlapping M peptides, severe patients exhibited significantly higher levels at day 7 than mild/moderate patients (GMs: 90 [95% CI 37–217] vs 19 [95% CI 10–39]; p= 0.0180; Figure 271 1b, Table S3). We did not observe any significant differences in the frequencies of IFN- γ 272 273 secreting cell responses to NP, NSPs, and ORFs overlapping peptides (Figure 1c-e, Table S3). For all five SARS-CoV-2 peptides we observed temporal differences in IFN- γ secreting 274 cells within each COVID-19 severity group (Figure 1, Table S3). Spike peptide: In the 275 asymptomatic group, IFN- γ secreting cells were significantly elevated on day 7 than on day 276 14 (GMs: 161 [95% CI 86-301] vs 92 [95% CI 44-189]; p=0.0039) and day 28 (102 [95% CI 277 278 49–209]; p=0.0042). For the mild/moderate group, levels significantly increased from 86 (95% CI 53–138) on day 7 to 142 (95% CI 78–257) on day 14 (p=0.0403). In the severe 279 group, significantly higher levels were observed on day 7 (70 [95% CI 29–165]; p=0.0381), 280 281 day 14 (117 [95% CI 52–260]; p=0.0058), and day 28 (108 [95% CI 33–348]; p=0.0037) relative to day 0 (23 95% CI 7-76). 282 M Peptide: In the asymptomatic patients, IFN- γ secreting cells were significantly higher on 283 day 14 (89 [95% CI 30–258]) compared to day 0 (GMs: 28 [95% CI 13–59]; p=0.0364) and 284 day 7 (GMs: 48 [95% CI 18–129]; p=0.0297). In the mild/moderate group, day 14 levels 285 were significantly higher compared to day 0 (p=0.0039), day 7 (p<0.0001), and day 28 286 (p=0.002). Additionally, day 28 levels were significantly higher than day 7 (p=0.0049). No 287 significant differences were observed between timepoints in the severe group. 288 289 NP Peptide: Among the asymptomatic group, a significant decline was observed from day 7 (71 [95% CI 33–153]) to day 28 (47 [95% CI 24–88]; p=0.0035). In the mild/moderate 290 group, IFN-γ secreting cell levels were significantly higher on day 14 (GMs: 67 [95% CI 34– 291 130]) compared to day 0 (GMs: 35 [95% CI 14-83]; p=0.0037), day 7 (GMs: 44 [95% CI 26-292 73]; p=0.0178), and day 28 (GMs: 47 [95% CI 24–91]; p=0.0003). No significant differences 293 were observed between timepoints in the severe group. For NSP peptide: a significant decline 294

- in IFN- γ secreting cells was observed within the mild/moderate group from 80 (95% CI 33–
- 194) at day 14 to 28 (95% CI 7–106) at day 28 (p=0.0316). For ORF peptide: a significant
- increase in IFN- γ secreting cells was observed in the mild/moderate group between day 0 (14
- 298 [95% CI 4–43]) and day 7 (GMs: 38 [95% CI 16–85]; p=0.0242).
- 299 Figure 1. Induction of a higher IFN-gamma cellular response to Spike protein on day of
- 300 diagnosis is associated with asymptomatic infection.
- 301 Frequencies of ex-vivo IFN- γ secreting cells against SARS-CoV-2 peptide pools spanning (a)
- spike protein, (b) M protein, c NP protein, (d) NSP proteins and (e) ORF proteins. Bars
- represent geometric mean and 95% CI.
- Linear mixed effects model with Tukey's multiple comparisons, was used, * P < 0.05.
- Number of samples analysed for: spike responses = 171, M responses = 136, NP responses =

162, NSP responses = 100 and ORF responses = 90.

307

We also assessed whether there were differences in IFN- γ secreting cell responses by location

309 (urban Nairobi and rural Kilifi) among asymptomatic and mild patients. Relative to Nairobi,

significantly higher levels of IFN- γ secreting cell responses to the SARS-CoV-2 spike

311 peptide (218 [95% CI 125–381] vs 56 [95% CI 28–110]; p=0.0057; Figure 2a) and NP

312 peptide (94 [95% CI 51–169] vs 19 [95% CI 8–48; p=0.0171; Figure 2c) were observed

among the asymptomatic patients in Kilifi on day 0. There were no significant differences

between Kilifi and Nairobi in the IFN- γ secreting cell responses to overlapping peptides for

the M protein for the asymptomatic patients (Figure 2b), nor for the spike, or NP, and or M

316 peptides among mild patients (Figure 2d–f). Data for severe patients are shown for Nairobi

participants only (Figure 2g–i), as we were unable to recruit severe patients in Kilifi.

Figure 2. Induction of a higher IFN-*γ* cellular response on the day of diagnosis is

319 associated with Kilifi participants.

- 320 Comparison of IFN-γ cellular responses between Kilifi and Nairobi COVID-19 patients with:
- asymptomatic disease for (a) Spike protein, (b) M protein, (c) NP protein; Mild disease for
- 322 (d) Spike protein, € M protein, (f) NP protein; and Severe disease for (g) Spike protein, (h) M
- 323 protein, (i) NP protein. Kilifi didn't have severe patients.
- Bars represent geometric mean and 95% CI. Kruskal–Wallis one-way ANOVA, with Dunn's
- multiple comparisons test, was performed. * P < 0.05, **P < 0.01.

326

327 Kinetics of cytokine and chemokine responses across COVID-19

328 severity groups and geographical location

- Asymptomatic patients consistently showed elevated levels of SDF-1 α at all time-points, but
- lower levels of all the other cytokines and chemokines measured and no detectable levels of
- IL-9 (Figure 3a). Similarly, for mild/moderate patients, high levels of SDF-1α (Figure 3b),
- 332 were observed at all timepoints whereas other cytokines and chemokines were secreted at low
- to intermediate levels. High cytokine and chemokines levels were seen among the severe
- patients with IL-Iβ, IL-6, IL-2, IFN-γ, GM-CSF, IFN-α, IL-7 and GRO-α decreasing over
- time, while MIP-1 α , MIP-I β , MCP-1, and SDF-1 α increased with time. Levels for IL1-ra, and
- 336 IL-9 were similar at all the time points (Figure 3c).

337 Figure 3. Kinetics of Cytokine and Chemokine Concentrations in COVID-19 Patients.

- 338 Mean of log10-transformed cytokine/chemokine concentrations plotted over time for (a)
- 339 Asymptomatic participants, (b) Mild/Moderate participants, and (c) Severe participants. * -
- 340 Levels for all participants were below detectable levels.

- 342 We compared asymptomatic against mild/moderate and severe participants to evaluate
- 343 differences among the clinical phenotypes. Mild/moderate participants had significantly
- higher levels of IL-18, IL-8, IL-1ra, IL-6, GM-CSF, IP-10, MCP-1, TNF-α, MIP-1α, IFN-γ,

345	IL-2, IL-7, IL-1 β , IL-9, Eotaxin and IFN- α than asymptomatic patients. The largest effect
346	sizes were observed with IL-18 (1.107, p<0.0001), IL-8 (1.105, p<0.0001) and IL-1ra,
347	(0.672, p=0.013). On the contrary, levels for SDF-1 α were significantly reduced among the
348	mild/moderate patients relative to the asymptomatic (effect size -0.182, p<0.0001) (Figure 4).
349	Severe participants had significantly higher levels for cytokines (IL-8, IL-18, IL-1ra, IL-6,
350	IP-10, MIP-1α, TNF-α, IL-9, IFN-γ, GM-CSF, IL-7, IL-1β, MCP-1, IL-2, GRO-α, Eotaxin
351	and IFN- α) compared to asymptomatic cases, except for IL-1a, IL-21 and MIP-I β which had
352	similar levels, and SDF-1 α (effect size -0.195, p<0.0001), which was significantly reduced.
353	The largest effect size was observed in IL-8 (1.754, p<0.0001), IL-18 (1.666, p<0.0001) and
354	IL-1ra (1.197, p<0.0001) (Figure 4).
355	For asymptomatic individuals, the cytokines and chemokine levels for IL-6, MIP-1 α , IL-18,
356	GRO- α , IL-2, IL-8, TNF- α and GM-CSF were significantly higher among Nairobi than Kilifi
357	patients. Comparisons for IL-6 (1.139, p<0.0001), MIP-1a (1.093, p=0.004) and IL-18
358	(1.025, p=0.002) had the largest effect sizes (Figure 4). For mild patients, all cytokines (IL-8,
359	IL-18, IL-1ra, MIP-1α, IL-6, IP-10, IFN-γ, TNF-α, MCP-1, GM-CSF, IL-9, IL-1β, Eotaxin,
360	IL-7, MIP-I β , and IFN- α) were significantly higher among Nairobi patients in comparison to
361	Kilifi patients except for GRO- α , IL-1 α , IL-2 and IL-21 which were similar. Notably, the
362	largest effect size for these comparisons was observed for IL-8 (1.69, p<0.0001), IL-18
363	(1.634, p<0.0001) and IL-1ra (1.355, p<0.001). On the other hand, SDF-1α (effect size -
364	0.161, p = 0.017) was significantly lower in Nairobi than in Kilifi patients.
365	Figure 4. Higher Cytokine and Chemokine concentrations in Asymptomatic and Mild
366	Patients from Nairobi Compared to Kilifi, and in Mild/Moderate and Severe Patients
367	Compared to Asymptomatic Individuals.
368	ns – not-significant, p value >0.05, empty means it was significant at p<0.05 - <0.0001. * -
369	Levels for all participants were below detectable levels.
370	
371	

372 Principal component analysis

- 373 The concentrations of the majority of the 21 cytokines and chemokines were positively
- 374 correlated with each other. However, the levels of SDF-1 α were negatively correlated with
- those of IL-2, IP-10, IL-7, IFN-γ, GM-CSF, and IL-18 (Figure S1). We retained the first three
- 376 principal components from a principal component analysis, accounting for 62% of the total
- variability in the 21 cytokines and chemokines (Figure S2a). IL-9, MIP-1α, TNF-α, MCP-1,
- MIP-I β , IL1-ra, IL-6, IL-I β , GRO- α and IL-8 were the most strongly associated with the first
- PC. The second PC was most strongly associated with IP-10, IFN-γ, GM-CSF, IL-2, IL-18,
- 380 IL-7, IFN- α , Eotaxin and SDF-1 α . The third PC was associated with IL-1 α and IL-21 (Figure
- S3). There was no clear separation among the mild/moderate and severe groups. However,
- data points for the asymptomatic participants clustered together demonstrating a much-
- reduced diversity of cytokine and chemokine levels than the other groups (Figure 5), and
- median PC scores did not change over the first month (Figure S2b).
- **Figure 5. Scatter plot by Severity at baseline.**
- **386** (a) PC1 vs PC2; (b) PC2 vs PC3
- 387

Among the symptomatic groups (mild/moderate/severe), a steady decline of all the PCs over 388 one month was observed, with a steep decline occurring between day 0 and day 7 (Figure 389 S2c). There was no apparent difference of the cytokine and chemokine responses between 390 391 asymptomatic participants from Kilifi and Nairobi (Figure S4a). For mild cases, Kilifi patients clustered together, although there was a slight overlap with Nairobi participants 392 (Figure S4b). Using biplots, there was no apparent difference between asymptomatic and 393 394 mild Kilifi patients (Figure S4c). For Nairobi, clinical phenotypes were asymptomatic, mild, moderate, and severe. We combined the mild and moderate, and observed no clear difference 395

- between the mild/moderate and severe groups, while the few asymptomatic participants
- 397 seemed to cluster together (Figure S4d).

398

399

401 Discussion and conclusion

In this study, we measured associations between the acute IFN- γ cellular, and 22 cytokine 402 and chemokine, immune response to SARS-CoV-2 (within a month of diagnosis) with 403 COVID-19 severity and possible modulation by differential environmental exposures in 404 urban and rural areas in Kenya. 405 As had been seen in earlier reports from Singapore, Netherlands, and Italy, which associated 406 increased IFN- γ secreting cells measured by ELISpot assay in the early phase of infection 407 with milder disease (38–40), we found that higher frequencies of an early IFN- γ cellular 408 409 response to SARS-CoV-2 spike overlapping peptides was associated with asymptomatic, compared to severe SARS-CoV-2 infection outcomes. This observation would suggest either: 410 1) that the IFN- γ cellular response contribute to protection against disease progression, or 2) 411 that developing severe COVID-19 depresses this response. The latter interpretation may be 412 supported by previous reports from China and USA reporting correlations of an early 413 induction of increased basal T-cell specific responses (CD4⁺ and CD8⁺ T) in COVID-19 414 patients with mild disease, which was suppressed among their severely sick counterparts 415 (41, 42).416 Whilst the concentrations of the pro-inflammatory cytokines and chemokines IL-6, IL-IB, 417 GRO-α, IFN-γ, GM-CSF, IFN-α, IL-7 and IL-2 in severe patients declined to basal levels at 418 day 28 from day of diagnosis, we found that the concentrations for the chemokines MIP-1 α . 419

420 MIP-I β , MCP-1, and SDF-1 α were increasing with time. This is to be expected as cytokines

421 and chemokines play different roles and at different times of the immune response to

422 infection. MIP-1 α , MCP-1 and MIP-I β are chemoattractant and play key roles in the

423 recruitments of leukocytes such as monocytes, T-cells, and neutrophil to the sites of infection

424 (43,44). Similarly increasing kinetics for MIP-1 α and MCP-1 in severe and fatal patients

425 were reported in Norway and China, respectively (45,46). Notably, we found that higher

426	concentrations of SDF-1 α were associated with asymptomatic individuals, hinting at a
427	potential protective role from severe disease progression. SDF-1 α (CXCL12), is a
428	chemokine involved in the recruitment of T-cells (47), CD34+ hematopoietic stem/progenitor
429	cells (48), lymphocytes and monocytes (49) to the site of infection further enhancing
430	inflammation. In contrast, studies from China and Bulgaria did not observe significant
431	differences in SDF-1 α levels among asymptomatic, mild, moderate, severe or fatal cases
432	(18,46,50). However, others have also implicated SDF-1 α in disease severity based on
433	genetic association studies in a single-centre study (51), although this finding was not
434	corroborated in multi-centre genome-wide association studies (52). SDF-1 α may aid in the
435	timely recruitment of T and other cells (47), to the sites of infection, enhancing viral
436	elimination, reduction in inflammation, and promotion of recovery.
437	We demonstrate that elevated levels of eighteen cytokines and chemokines were associated
438	with severe COVID-19, in agreement with previous reports linking them to severe lung
439	injury and ARDS (17-22,53). However, the associations with IL-8, IL-18 and IL-1ra, had the
440	strongest effect sizes in the current study. IL-8, has been implicated in the activation and
441	recruitment of neutrophils to the site of infection, thereby promoting inflammation (54). IL-
442	18 amplifies the immune response by inducing the production of IFN- γ by T-cells and natural
443	killer cells (55). Thus, IL-8 and IL-18 could amplify the excessive inflammation that
444	characterises severe COVID-19. On the contrary, IL1-ra is known to suppress the production
445	of proinflammatory cytokines such as IL-1 and TNF- α (56), and probably helps mitigate the
446	effects of excessive inflammation, thus reducing tissue damage and associated mortality.
447	In parallel to the reduced rates of severe COVID-19 and associated deaths in SSA relative to
448	North America and Europe, we and others have suggested higher rates of severe COVID-19
449	in cities compared to rural areas in SSA (28). Whilst this difference could be explained by
450	higher levels of SARS-CoV-2 transmission in busy metropolitan cities, or by more complete

reporting of cases (28,57,58), we wondered whether there were also plausible biological 451 explanations. We compared inflammatory cytokine and chemokine levels, and found that the 452 asymptomatic patients from Nairobi had higher levels of 8 cytokines and chemokines than 453 their asymptomatic counterparts from Kilifi, with IL-6, IL-18 and MIP-1 α , having the 454 strongest associations. Similarly, levels of 16 cytokines and chemokines were higher among 455 mild- Nairobi, than Kilifi, COVID-19 patients with IL-8, IL-18 and IL-1ra being the most 456 457 differentially secreted. Moreover, the basal frequencies of IFN- γ secreting cells in asymptomatic patients from Nairobi, relative to those of their Kilifi counterparts, were 458 459 reduced. Collectively, these findings would suggest that the immune response to SARS-CoV-2 is less inflammatory among residents of rural areas (59). 460 Our study was faced with a few limitations. Firstly, our data are incomplete for some of the 461 patients due to missed follow-ups, or due to unavailability of adequate numbers of PBMCs to 462 quantify IFN- γ cellular responses to the full spectrum of the peptide pools corresponding to 463 all the different SARS-CoV-2 proteins. However, our analyses are assumed valid under the 464 missing at random mechanism given the likelihood approach (60). Secondly, we had 465 difficulties recruiting asymptomatic patients in Nairobi and were unable to recruit severe 466 cases in Kilifi and thus the sample size is relatively small. 467 In conclusion, although severe disease was rare in Kenya, the inflammatory cytokine profile 468 in patients with severe COVID is similar to that of North American and European severe 469 470 COVID-19 patients. However, just like the early IFN- γ secreting cellular response, increased levels of the chemokine, SDF-1a, were associated with asymptomatic SARS-CoV-2 471 infection, suggesting a potential role of these responses in protection against disease 472 progression. Finally, the differential cytokine and chemokine, and IFN- γ cellular responses 473 between urban Nairobi and rural Kilifi patients suggest a plausible biological explanation for 474 the increased frequency of severe COVID-19 in African SSA cities relative to rural areas. 475

- Together, these findings provide insights into potentially COVID-19 protective immune
- 477 responses, and their modulation by differential environmental exposures. Nonetheless,
- 478 additional studies are required to extend and replicate these important findings as they could
- inform future control of COVID-19 and empower the control of similar pandemics.

480

482 Acknowledgments

- 483 We thank the field workers, laboratory staff and healthcare workers involved in the
- 484 longitudinal blood sampling. We appreciate all the study participants.

486 **References**

- 1. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al. COVID-
- 488 19 in the 47 countries of the WHO African region: a modelling analysis of past trends and
- future patterns. Lancet Glob Health. 2022 Aug;10(8):e1099–114.
- 490 2. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. Science.
- 491 2021 Jan;371(6524):27–8.
- 492 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A
- 493 Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-
- 494 Vaccine Hypothesis to the Test. Earth Syst Environ. 2021 Sep 1;5(3):799–810.
- 495 4. Diop BZ, Ngom M, Pougué Biyong C, Pougué Biyong JN. The relatively young and rural
- 496 population may limit the spread and severity of COVID-19 in Africa: a modelling study.
- 497 BMJ Glob Health. 2020 May;5(5):e002699.
- 498 5. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What
- 499 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of
- the SARS-CoV-2 Virus? Int J Environ Res Public Health. 2021 Aug 16;18(16):8638.
- 501 6. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al. Peptide
- 502 microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from
- 503 Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-
- sectional study. Lancet Microbe. 2023 Apr 1;4(4):e215–27.
- 5057. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
- reactive T cells in healthy donors and patients with COVID-19. Nature. 2020 Nov

507 12;587(7833):270–4.

508 8. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-

- specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
- 510 Nature. 2020 Aug;584(7821):457–62.
- 511 9. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of
- 512 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
- 513 Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15.
- 10. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.
- 515 Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute
- respiratory distress syndrome. Sci Immunol. 2020 Jun 26;5(48):eabd2071.
- 517 11. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and
 518 cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct
 519 2;370(6512):89–94.
- 520 12. Naidoo P, Ghazi T, Chuturgoon AA, Naidoo RN, Ramsuran V, Mpaka-Mbatha MN,
- et al. SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: An
- epidemiological and immunological perspective. Environ Int. 2021 Nov 1;156:106695.
- 523 13. Anyanwu MU. The association between malaria prevalence and COVID-19 mortality.
 524 BMC Infect Dis. 2021 Sep 19;21(1):975.
- Mogensen TH, Paludan SR. Virus-cell interactions: impact on cytokine production,
 immune evasion and tumor growth. Eur Cytokine Netw. 2001;12(3):382–90.
- 527 15. Mogensen TH, Paludan SR. Molecular Pathways in Virus-Induced Cytokine
 528 Production. Microbiol Mol Biol Rev. 2001 Mar;65(1):131.

- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in
 COVID-19. J Infect. 2020 Jun;80(6):607–13.
- 531 17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
- infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb

533 15;395(10223):497–506.

- 18. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum Cytokine and Chemokine
 Profile in Relation to the Severity of Coronavirus Disease 2019 in China. J Infect Dis.
 2020 Aug 4;222(5):746–54.
- 537 19. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune
- Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect

539 Dis Off Publ Infect Dis Soc Am. 2020 Jul 28;71(15):762–8.

- 540 20. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.
- 541 Patterns of cytokine and chemokine expression in peripheral blood of patients with
- 542 COVID-19 associated with disease severity. Int J Immunopathol Pharmacol. 2023
- 543 Dec;37:039463202311636.
- 544 21. Ndoricyimpaye EL, Van Snick J, Robert R, Bikorimana E, Majyambere O,

545 Mukantwari E, et al. Cytokine Kinetics during Progression of COVID-19 in Rwanda

- Patients: Could IL-9/IFNγ Ratio Predict Disease Severity? Int J Mol Sci. 2023 Jul
- 547 31;24(15):12272.
- Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal Cytokine
 Profile in Patients With Mild to Critical COVID-19. Front Immunol [Internet]. 2021 Dec 6
 [cited 2024 Apr 19];12. Available from:

551	https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.763292/ful
552	1

553	23. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
554	lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
555	infected patients. eBioMedicine [Internet]. 2020 May 1 [cited 2024 Jul 18];55. Available
556	from: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30138-
557	9/fulltext
558	24. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore
559	SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for
560	GM-CSF in severe COVID-19. Sci Immunol. 2021 Mar 10;6(57):eabg9873.
561	25. Darif D, Hammi I, Kihel A, Saik IEI, Guessous F, Akarid K. The pro-inflammatory
562	cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. 2021
563	Apr;153:104799.
564	26. Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, et al. Kinetics of naturally
565	induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among
566	SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an
567	observational study. Wellcome Open Res. 2023 Aug 17;8:350.
568	27. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021
569	Feb;184(4):861–80.
570	28. Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, et al. COVID-19
571	transmission dynamics underlying epidemic waves in Kenya. Science. 2021 Nov

572 19;374(6570):989–94.

- 573 29. NIH. COVID-19 Treatment Guidelines. 2021 [cited 2024 Jun 13]. Clinical Spectrum
- 574 of SARS-CoV-2 Infection. Available from:
- 575 https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
- 576 30. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and
- antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-
- 578 CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet
- 579 Microbe. 2022 Jan;3(1):e21–31.
- 580 31. Merck KGaA. Sigmaaldrich Belysa® Immunoassay Curve Fitting Software,
- 581 Darmstadt, Germany. 2022 [cited 2024 Apr 11]. Belysa® Immunoassay Curve Fitting
- 582 Software. Available from: https://www.sigmaaldrich.com/KE/en/services/software-and-
- 583 digital-platforms/belysa-immunoassay-curve-fitting-software
- 584 32. Gelman A, Hill J. Higher Education from Cambridge University Press. Cambridge
- 585 University Press; 2006 [cited 2024 Oct 28]. Data Analysis Using Regression and
- 586 Multilevel/Hierarchical Models. Available from:
- 587 https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-
- 588 multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983
- 589 33. R Core Team. R Foundation for Statistical Computing, Vienna, Austria. 2023 [cited
- 590 2024 Mar 8]. R: A language and environment for statistical computing. Available from:
- 591 https://www.R-project.org/
- 592 34. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate
- 593 Data Analyses [Internet]. 2020 [cited 2024 Mar 8]. Available from: https://CRAN.R-
- 594 project.org/package=factoextra

- 595 35. Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2024 Mar 8]. (R package
- version 1.0.12). Available from: https://cran.r-
- 597 project.org/web/packages/pheatmap/index.html
- 598 36. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Cham: Springer
- International Publishing, New York; 2016 [cited 2024 Mar 8]. (Use R!). Available from:
- 600 http://link.springer.com/10.1007/978-3-319-24277-4
- 601 37. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.
- 602 2023 [cited 2024 Apr 11]. Prism GraphPad. Available from:
- 603 https://www.graphpad.com/features
- 38. Tan AT, Linster M, Tan CW, Bert NL, Chia WN, Kunasegaran K, et al. Early
- 605 induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance
- and mild disease in COVID-19 patients. Cell Rep [Internet]. 2021 Feb 9 [cited 2024 Aug
- 607 3];34(6). Available from: https://www.cell.com/cell-reports/abstract/S2211-
- 608 1247(21)00041-3
- 609 39. Rümke LW, Smit WL, Bossink A, Limonard GJM, Muilwijk D, Haas LEM, et al.
- 610 Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19. Front
- Immunol [Internet]. 2023 Apr 17 [cited 2024 Sep 13];14. Available from:
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/f
 ull
- 40. Garofalo E, Biamonte F, Palmieri C, Battaglia AM, Sacco A, Biamonte E, et al.
- 615 Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of
- 616 IFNγ-releasing cells: An exploratory study. PLOS ONE. 2023 Feb 9;18(2):e0281444.

- 41. Zeng Q, Li YZ, Dong SY, Chen ZT, Gao XY, Zhang H, et al. Dynamic SARS-CoV-
- 618 2-Specific Immunity in Critically Ill Patients With Hypertension. Front Immunol
- 619 [Internet]. 2020 Dec 10 [cited 2024 Sep 13];11. Available from:
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596684/ful
- 621

1

- 42. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive
- features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell
- 624 Rep [Internet]. 2021 Jul 20 [cited 2024 Sep 13];36(3). Available from:
- https://www.cell.com/cell-reports/abstract/S2211-1247(21)00827-5
- 43. Takahashi M, Galligan C, Tessarollo L, Yoshimura T. Monocyte Chemoattractant
- 627 Protein-1 (MCP-1), Not MCP-3, Is the Primary Chemokine Required for Monocyte

628 Recruitment in Mouse Peritonitis Induced with Thioglycollate or Zymosan A. J Immunol

- Baltim Md 1950. 2009 Sep 1;183(5):3463–71.
- 44. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential Migration of
 Activated CD4+ and CD8+ T Cells in Response to MIP-1α and MIP-1β. Science. 1993
 Apr 16;260(5106):355–8.
- 45. Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE,
- et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated
- with respiratory failure in COVID-19. Sci Rep. 2020 Dec 10;10:21697.
- 46. Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, et al. Temporal profiling of plasma
 cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients.
 Signal Transduct Target Ther. 2020 Jun 19;5(1):1–3.

639	47. Nanki T, Lipsky PE. Cutting Edge: Stromal Cell-Derived Factor-1 Is a Costimulator
640	for CD4+ T Cell Activation. J Immunol. 2000 May 15;164(10):5010-4.
641	48. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The Chemokine SDF-1
642	Is a Chemoattractant for Human CD342 Hematopoietic Progenitor Cells and Provides a
643	New Mechanism to Explain the Mobilization of CD342 Progenitors to Peripheral Blood.
644	49. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly
645	efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp
646	Med. 1996 Sep 1;184(3):1101–9.
647	50. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.
648	Patterns of cytokine and chemokine expression in peripheral blood of patients with
649	COVID-19 associated with disease severity. Int J Immunopathol Pharmacol. 2023
650	Dec;37:039463202311636.
651	51. Korayem OH, Ahmed AE, Meabed MH, Magdy DM, Abdelghany WM. Genetic clues
652	to COVID-19 severity: exploring the stromal cell-derived factor-1/CXCL12 rs2839693
653	polymorphism in adult Egyptians. BMC Infect Dis. 2023 Oct 19;23:702.
654	52. Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, et al. GWAS
655	and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature.
656	2023 May;617(7962):764-8.
657	53. Zhang Z, Ai G, Chen L, Liu S, Gong C, Zhu X, et al. Associations of immunological
658	features with COVID-19 severity: a systematic review and meta-analysis. BMC Infect Dis.
659	2021 Aug 3;21(1):738.

660	54.	Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential
661	in	volvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol.
662	19	994;56(5):559–64.

- 55. Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding
- Protein. Front Immunol [Internet]. 2013 Oct 8 [cited 2024 Aug 21];4. Available from:
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00289/full

666 56. Dayer JM. Evidence for the biological modulation of IL-1 activity: The role of IL-

- 667 1Ra. Clin Exp Rheumatol. 2001 Nov 30;20:S14-20.
- 668 57. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-

CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second
Waves of Infections, South Africa, July 2020–March 2021. Emerg Infect Dis. 2021
Dec;27(12):3020–9.

58. Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of

673 SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level
674 of spread during the first wave of the pandemic. EClinicalMedicine. 2021 May
675 1;35:100880.

59. Samandari T, Ongalo JB, McCarthy KD, Biegon RK, Madiega PA, Mithika A, et al.
Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.
J Clin Invest. 133(13):e170011.

681

^{679 60.} Little RJA, Rubin DB. Statistical Analysis with Missing Data. John Wiley & Sons;
680 2019. 462 p.

682 Supporting information

- **Figure S1.** Correlation matrix of 21 cytokines across all time points from 400 patients.
- 684 Pearson's correlation coefficients are visualised, with red indicating positive correlations,

blue negative correlations, and white representing no correlation.

- **Figure S2. Principal component analysis of the cytokines. a)** Scree-plot showing that the
- 687 first 3 principal components explained 62% of variability in the cytokines data for all
- 688 participants; (b) Line plots for the first 3 principal component illustrating trends over time for

asymptomatic participants; and (c) Line plots for the first 3 principal component illustrating

trends over time for symptomatic (mild, moderate and severe) participants.

- 691 Figure S3. Cytokines loading on the first three principal components (PC1–PC3). The
- color scale indicates the loading value, with red indicating a higher positive loading, blue a
- higher negative loading and light-yellow minimal loading.

694 Figure S4. Scatter plots showing cytokine data for participants grouped by location and

695 **clinical phenotype. (a)** Asymptomatic participants, **(b)** mild cases, **(c)** participants from

- 696 Kilifi, and (d) participants from Nairobi. Each point represents an individual's cytokine
- 697 measurement, allowing for a visual assessment of cytokine variability across different groups
- 698 based on location and clinical presentation.

699 **Table S1. Peptides Sequences.** Each entry represents a distinct peptide along with its


associated properties. The pooling strategy for the 10 peptide pools used is shown below.

- 701 Table S2. Sample size for each peptide. Number of participants sampled for each peptide
- across different clinical phenotypes (asymptomatic, mild/moderate, severe) and time points
- 703 (Day 0, 7, 14, 28).

704 Table S3. Associations of SARS-CoV-2 Peptides (Spike, M, NP, NSP, and ORF) with


705 asymptomatic, mild/moderate, and severe clinical phenotypes over time. Tukey's

- multiple comparisons test was used to assess differences within and between clinical
- phenotypes across different time points. Bold p values are significant, p < 0.05.





- Asymptomatic
- Mild/Moderate


Severe












				MIP-1a	
ns				SDF-1a	1.5
				IL-1b	
ns				-	1.1
	ns			IL-2	0.7
ns				IP-10	0.1
				IL-6	0.3
ns				IL-7	
				IL-8	-0.1
ns				Eotaxin	
ns				IL-1ra	
ns				IFN-g	
				GMCSF	
				TNF-a	
ns		ns	ns	MIP-1b	
ns				IFNa	
ns				MCP-1	
ns*				IL-9	
	ns	ns		GRO-a	
ns	ns	ns	ns	IL-1a	
				IL-18	
ns	ns	ns	ns	IL-21	
Kilifi vs Nairobi (Asymptomatic only)	Kilifi vs Nairobi (Mild only)	Asymptomatic vs Mild/Moderate	Asymptomatic vs Severe		






Figure 5